Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1197-1206

  Hamann, Christine ^a   Picke, Ann Kristin ^b   Campbell, Graeme M ^c   Balyura, Mariya ^b   Rauner, Martina ^b   Bernhardt, Ricardo ^e   Huber, Gerd ^f   Morlock, Michael M ^f   Günther, Klaus Peter ^a,g   Bornstein, Stefan R ^b,d,g   Glüer, Claus C ^c   Ludwig, Barbara ^b,d,g   Hofbauer, Lorenz C ^b,g  

^a Department of Orthopedics ^*  (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Section Molecular Imaging   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f HAMBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^g CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CARBOXYLATED OSTEOCALCIN; CREATININE; GLUCOSE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; TARTRATE RESISTANT ACIDIC PHOSPHATASE; UNCLASSIFIED DRUG; UREA;

ACID PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE REGENERATION; BONE STRENGTH; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FRACTURE HEALING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HISTOLOGY; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; TRABECULAR BONE; UREA BLOOD LEVEL;

ANIMALS; BIOMECHANICAL PHENOMENA; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BONE REGENERATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMUR; FRACTURE HEALING; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; MALE; PANCREAS; PARATHYROID HORMONE; RATS; RATS, ZUCKER; X-RAY MICROTOMOGRAPHY;

EID: 84897905659     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1960     Document Type: Article

References (29)

1. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2009;84:45-55.
2. Petit MA, Paudel ML, Taylor BC, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010;25:285-291.
3. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317-1328. (Pubitemid 351339677)
4. Hamann C, Kirschner S, Günther KP, Hofbauer LC. Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8:297-305.
5. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045-5055.
6. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28:313-324.
7. Liu Z, Aronson J, Wahl EC, et al. A novel rat model for the study of deficits in bone formation in type-2 diabetes. Acta Orthop. 2007;78:46-55. (Pubitemid 46570257)
8. Reinwald S, Peterson RG, Allen MR, Burr DB. Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab. 2009;296:E765-E774.
9. Hamann C, Goettsch C, Mettelsiefen J, et al. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab. 2011;301:E1220-1228.
10. Hamann C, Rauner M, Höhna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013;28:627-638.
11. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausalwomenwith osteoporosis: a randomized trial. Ann Intern Med. 2007;146:326-339. (Pubitemid 351650593)
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441. (Pubitemid 32402100)
13. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-2039. (Pubitemid 350106710)
14. Dobnig H, Piswanger-Sölkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91:3355-3363. (Pubitemid 44402104)
15. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:1277-1284.
16. Buie HR, Campbell GM, Klinck RJ, MacNeil JA, Boyd SK. Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis. Bone. 2007;41:505-515. (Pubitemid 47385446)
17. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468-1486.
18. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone. 1993;14:595-608. (Pubitemid 23198821)
19. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
20. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-420.
21. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481:314-320.
22. Clemens TL, Cormier S, Eichinger A, et al. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol. 2001;134:1113-1136. (Pubitemid 33097241)
23. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456-469. (Pubitemid 47208519)
24. Rosa BV, Blair HT, Vickers MH, Knight CG, Morel PC, Firth EC. Serum concentrations of fully and undercarboxylated osteocalcin do not vary between estrous cycle stages in Sprague-Dawley rats. Endocrine. 2013;44:809-811.
25. Morishima Y, Kamisato C, Honda Y, Furugohri T, Shibano T. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. Thromb Res. 2013;131:59-63.
26. Haffa A, Krueger D, Bruner J, et al. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res. 2000;15:872-878. (Pubitemid 30233410)
27. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. 2000;11:79-85. (Pubitemid 30164202)
28. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg. 2011;93:1583-1587.
29. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausalwomenwith distal radial fractures. J Bone Miner Res. 2010;25:404-414.